Safety and effectiveness of peficitinib 100 mg/day in patients achieving clinical remission from a long-term open-label extension study in Japan, Korea, and Taiwan (RAJ2).
Yoshiya TanakaTsutomu TakeuchiYoshiaki MoritaYuichiro KanekoWataru TeradaPublished in: Modern rheumatology (2023)
Long-term peficitinib treatment at a dose of 100 mg/day was generally well tolerated and, following induction therapy, maintained effectiveness through to W48.
Keyphrases
- end stage renal disease
- open label
- randomized controlled trial
- systematic review
- ejection fraction
- chronic kidney disease
- clinical trial
- prognostic factors
- peritoneal dialysis
- stem cells
- squamous cell carcinoma
- systemic lupus erythematosus
- radiation therapy
- phase ii
- bone marrow
- cell therapy
- patient reported outcomes